SCHEMBL19974836

SCHEMBL19974836

O=CN(Cc1ccccc1)C(CC1CCC1)C(=O)O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ATM Q13315 1/20 0.44
NPC1 O15118 1/20 0.39
RAB9A P51151 1/20 0.39
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
PKM P14618 1/20 0.38
EPHX2 P34913 1/20 0.37
AGER Q15109 3/20 0.37
MTNR1A P48039 1/20 0.37
AGTR1 P30556 1/20 0.37
LTB4R Q15722 1/20 0.37
LTB4R2 Q9NPC1 1/20 0.37
LTA4H P09960 1/20 0.37
MDM2 Q00987 1/20 0.37
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
CHRNB2 P17787 1/20 0.36
CHRNB4 P30926 1/20 0.36
CHRNA3 P32297 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19975421 0.90 ATM (0.43) ATMNPC1RAB9AMEN1KMT2A
SCHEMBL21176378 0.85 ATM (0.42) ATMNPC1RAB9AMEN1KMT2A
SCHEMBL841071 0.83 ATM (0.48) ATMNPC1RAB9AMEN1KMT2A
SCHEMBL840766 0.83 ATM (0.48) ATMNPC1RAB9AMEN1KMT2A
SCHEMBL9076021 0.79 ATM (0.53) ATMNPC1RAB9AMEN1KMT2A
SCHEMBL9076016 0.79 ATM (0.53) ATMNPC1RAB9AMEN1KMT2A
SCHEMBL27319185 0.78 CYP1A2 (0.47) PKMMMECPA1ALDH1A1HPGD
SCHEMBL8044507 0.77 CPA3 (0.45) NPC1RAB9AMEN1KMT2ACHRNB2
SCHEMBL19975346 0.74 MMP1 (0.48) NPC1RAB9AMEN1KMT2ALTA4H
SCHEMBL21176355 0.73 SMN1; SMN2 (0.44) ATMNPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220356148-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2022-11-10 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-11091428-B2 Antiviral compounds HAPLOGEN GMBH (AT) 2021-08-17 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
US-20190225575-A1 ANTIVIRAL COMPOUNDS LUNIS CONSULTING GMBH (AT) 2019-07-25 US disclosed
EP-3512836-A1 ANTIVIRAL COMPOUNDS Haplogen GmbH (AT) 2019-07-24 EP disclosed
WO-2018050631-A1 ANTIVIRAL COMPOUNDS HAPLOGEN GMBH (AT) 2018-03-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190225575-A1 ANTIVIRAL COMPOUNDS PLA2G1B, PLA2G12A, PLA2G4C ATM 4579/4885NPC1 753/4885RAB9A 1576/4885
US-20220356148-A1 ANTIVIRAL COMPOUNDS PLA2G12A, PLA2G1B, PLA2G4C ATM 4543/4885NPC1 1213/4885RAB9A 1334/4885
US-11091428-B2 Antiviral compounds PLA2G1B, PLA2G12A, PLA2G4C ATM 4579/4885NPC1 753/4885RAB9A 1576/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.